UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
As a new crypto investor, it's crucial to know what to watch out for to avoid costly mistakes. Equip yourself with knowledge to navigate the market safely.
27,825 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Want income that compounds over time? These high-yield energy stocks offer reliable payouts and growth potential. Lea...
This analysis breaks down the Q4 2025 earnings transcript for quest resource (qrhc), highlighting revenue, margins, a...
A leadership reshuffle at ICE has intensified scrutiny of the revolving door between private prison firms and federal...
Investors eye Hewlett Packard Enterprise’s 2026 earnings call for guidance on AI demand, GreenLake growth, and capita...
Microsoft is shifting toward building its own AI backbone. This article explores what that means for investors, how i...
Kyntra Bio (KYNB) is on investors' radar as 2025 earnings wrap up. This guide breaks down what the Q4 results mean, h...
PowerFleet is reshaping fleet management with AI-powered IoT. This guide breaks down what to expect from powerfleet (...
Kyndryl’s latest quarterly results triggered a notable stock move as earnings fell short of expectations. This articl...
A single industrial stock riding infrastructure gains from the AI data-center buildout. Learn how to spot durable dem...
AT&T has been through a long turnaround, shedding assets and tightening the balance sheet. This article weighs the ca...
A high-stakes NBA scenario puts investor attention on payroll, sponsorships, and market bets. The potential LeBron mo...